India to Malta: Acarbose Export Trade Route

To import finished pharmaceutical formulations containing Acarbose into Malta, companies must obtain a Marketing Authorisation (MA) from the Malta Medicines Authority (MMA). Applications are submitted electronically via the Common European Submission Portal (CESP) in the electronic Common Technical Document (eCTD) format. As of January 2022, paper submissions are no longer accepted. (medicinesauthority.gov.mt)

The MMA offers several procedures for obtaining an MA:

• National Procedure: For products not authorized in any EU/EEA Member State.

• Mutual Recognition Procedure (MRP): For products already authorized in another EU/EEA Member State.

• Decentralized Procedure (DCP): For simultaneous applications in multiple EU/EEA Member States.

Additionally, under Article 126(a) of Directive 2001/83/EC, the MMA may grant authorization for products authorized in another EU/EEA Member State but not in Malta, primarily to address public health needs. This authorization is valid for up to three years. (servizz.gov.mt)

Applicants must ensure that manufacturing sites comply with Good Manufacturing Practice (GMP) standards. The MMA conducts GMP inspections to verify compliance. (medicinesauthority.gov.mt) Timelines for approval vary depending on the procedure and the completeness of the application. Applicants should consult the MMA for specific fees associated with each procedure.

Indian manufacturers exporting Acarbose formulations to Malta must adhere to EU GMP standards. The MMA conducts GMP inspections to ensure compliance. (medicinesauthority.gov.mt) In June 2024, the MMA issued a Statement of Non-Compliance with GMP for Akriti Pharmaceuticals, an Indian company, following a routine onsite inspection that revealed significant deficiencies. This underscores the importance of maintaining stringent GMP standards to ensure uninterrupted market access.

In October 2025, the MMA and the Superintendence of Public Health issued a joint statement reaffirming the quality and efficacy of generic medicines, emphasizing that they meet the same EU regulations for quality, safety, and efficacy as all other medicines. (gov.mt) This statement aims to bolster confidence in generic medicines, including those imported from India.

Additionally, as of January 2022, the MMA mandated that all applications be submitted electronically via CESP in eCTD format, discontinuing paper submissions. (medicinesauthority.gov.mt) This shift streamlines the application process and aligns with European standards.

Acarbose is an alpha-glucosidase inhibitor used primarily in the management of type 2 diabetes mellitus. In Malta, the prevalence of diabetes has been increasing, with recent data indicating that approximately 10% of the adult population is affected. This rise is attributed to factors such as an aging population, sedentary lifestyles, and dietary habits. The Maltese healthcare system provides universal coverage, ensuring that medications like Acarbose are accessible to patients. While specific market size data for Acarbose in Malta for 2024-2025 is not readily available, the increasing prevalence of diabetes suggests a growing demand for antidiabetic medications. Malta relies heavily on imports for its pharmaceutical needs, with limited domestic manufacturing capabilities. Therefore, the majority of Acarbose formulations are imported to meet local demand.

Malta, as a member of the European Union, applies the EU's Common External Tariff. Pharmaceutical products classified under HS code 30049099, which includes Acarbose formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate. Additionally, Malta does not impose Value Added Tax (VAT) on pharmaceutical products, making the importation of these goods duty-free. There are no Free Trade Agreements (FTAs) between India and Malta that specifically affect pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Acarbose formulations imported into Malta.

India is a significant supplier of Acarbose formulations to Malta, accounting for 0.4% of India's total Acarbose formulation exports, valued at $6.8 million. The primary Indian exporter is Aurobindo Pharma Limited, with shipments routed through ports such as Hyderabad Air and Vizag Sea. The main importer in Malta is APL Swift Services (Malta) Ltd. While specific data on other countries supplying Acarbose to Malta is not detailed, it is common for European Union member states to source pharmaceuticals from within the EU due to regulatory harmonization and logistical advantages. India's pharmaceutical industry is known for its cost-effective production, often offering competitive pricing compared to manufacturers in China and the European Union. This pricing advantage, coupled with India's compliance with international quality standards, positions Indian exporters favorably in the Maltese market.

India is a leading global hub for generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2025. The country's extensive manufacturing infrastructure includes numerous facilities approved by the U.S. FDA and WHO-GMP, ensuring compliance with stringent international quality standards. For instance, Granules India Limited's Genome Valley facility in Hyderabad received U.S. FDA approval in August 2025, adding significant capacity for finished dosage forms. This robust infrastructure enables cost-effective production of Acarbose formulations, including tablets and capsules, making India a preferred source for these products globally.

When comparing Acarbose formulations from India, China, and the European Union, several factors come into play:

• Cost: Indian manufacturers offer competitive pricing due to lower production costs and economies of scale. While specific per-unit pricing for Acarbose formulations is proprietary, India's cost advantage is well-documented across various pharmaceutical products.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for quality, with many facilities holding U.S. FDA and WHO-GMP certifications. This positions Indian products favorably against Chinese counterparts, which may face scrutiny over quality concerns. European manufacturers are also recognized for high-quality standards but often at higher price points.

• Regulatory Acceptance in Malta: Malta, as an EU member state, adheres to stringent regulatory standards. Indian manufacturers with EU-GMP certifications are well-positioned to meet these requirements, facilitating smoother market entry.

• Supply Reliability: Indian pharmaceutical companies have demonstrated a reliable supply track record, supported by robust manufacturing capacities and compliance with international standards.

The India-Malta supply chain for Acarbose formulations is underpinned by India's substantial manufacturing capacity. Facilities like Granules India's Genome Valley site have expanded production capabilities, adding 10 billion doses of formulation capacity as of August 2025. These facilities are equipped with advanced packaging and cold chain logistics to ensure product integrity during transit. Indian manufacturers maintain a strong regulatory compliance record, with successful inspections by authorities such as the U.S. FDA and EU agencies. For example, Dr. Reddy's Laboratories' formulations manufacturing facilities in Visakhapatnam received a Voluntary Action Indicated (VAI) classification from the U.S. FDA in August 2024, indicating compliance with good manufacturing practices. There are no significant reports of supply disruptions in recent years, and ongoing capacity expansions suggest a commitment to meeting global demand.

For Maltese buyers sourcing Acarbose formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements to align with your procurement needs.

• Payment Terms: Standard payment terms in India-Malta pharmaceutical trade often include letters of credit or advance payments. Negotiate terms that balance financial security and cash flow considerations.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications (e.g., EU-GMP), and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers have a history of compliance with international regulatory standards, as evidenced by successful inspections and certifications.

By implementing these strategies, Maltese buyers can establish a reliable and cost-effective supply chain for Acarbose formulations from India.

By adhering to this comprehensive approach, Malta-based companies can effectively qualify Indian suppliers of Acarbose formulations, ensuring compliance with EU regulations and safeguarding product quality.